Anti-CD25 single-domain antibody and use thereof
By designing single-domain antibodies with specific amino acid sequences, the problems of large molecular weight, poor infiltration and high immunogenicity of existing antibodies when targeting CD25 are solved, achieving highly specific binding to CD25 and killing tumor cells, which is suitable for tumor treatment and detection.
WO2026114231A1PCT designated stage Publication Date: 2026-06-04ASSEMBLY MEDICINE LLC
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- ASSEMBLY MEDICINE LLC
- Filing Date
- 2025-11-25
- Publication Date
- 2026-06-04
Smart Images
Figure CN2025137569_04062026_PF_FP_ABST
Abstract
Disclosed in the present invention are an anti-CD25 single-domain antibody and the use thereof. Specifically, disclosed in the present invention is an anti-human CD25 specific single-domain antibody. Also disclosed are a coding sequence encoding the single-domain antibody or a VHH chain thereof, a corresponding expression vector and host cell, and a method for producing the single-domain antibody of the present invention. The single-domain antibody of the present invention has high affinity and high specificity, and can be used for CD25 detection and targeted therapy.
Need to check novelty before this filing date? Find Prior Art